Post-trial access is crucial in bridging the gap between trial completion and local treatment availability, ensuring no participants are left behind. linkedin.com/posts/paul-o-al…
Paul Aliu retweeted
Novartis announces late-breaking data at #ERA24 showing proteinuria reduction in patients with C3G #NovartisNews go.novartis.social/450Dihw
Paul Aliu retweeted
PJ view: Inequity of access to medicines for compassionate use must end
pharmaceutical-journal.com/a…
Great to be back at #IMD for constructive, inspiring and energising dialogues about the state of the world, global economy, businesses as vehicles for change, and making an impact. It’s been 10 years since our executive MBA program, so was awesome catchin…lnkd.in/ektFRBu8
Paul Aliu retweeted
NICE says genetic testing before initiating clopidogrel is a cost-effective use of NHS resources for patients at risk of stroke
pharmaceutical-journal.com/a…
Excellent news re this recent FDA approval of an ultra-rare disease treatment. Remember Novartis making this compound available to patients via Compassionate Use (CU) a few years ago.
Congratulations to the PharmingTeam!
#rare…lnkd.in/et_8Y7CK lnkd.in/e_cziFxS
2
48
Paul Aliu retweeted
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, our compassionate use program can provide this lifeline, and we’re further exploring our data to improve early access to medicines.
Find out more.
Providing access to much needed treatments
"The primary purpose of Compassionate Use/Expanded Access is to provide treatment and it is not targeting research. However, it is increasingly considered as a source of real-world data"
Delighted to share our recent publication o…lnkd.in/ev5PJi5e lnkd.in/ead7NJAq
3
95
Paul Aliu retweeted
In a first-of-its-kind study using data from our compassionate use program, we discovered vast disparities in requested access linked to national:
-level of economic development
-availability of regulations
-number of clinical trials
Discover more:
Delighted to share our latest publication out today in JAMA Health Forum!
Eight-factor regulatory framework proposed to ensure robust #compassionateuse regulations at a country level that would facilitate speedy, ethical, responsi…lnkd.in/eZX4PE-b lnkd.in/egDdbRJM
Total antibiotic consumption in England declined by 15.1% between 2017 and 2021…….
Antibiotic prescribing target hit one year early in England
pharmaceutical-journal.com/a…
1
Paul Aliu retweeted
Exclusive: "Exciting" trial results will show adverse drug reactions reduced by nearly one third after genetic testing, says lead researcher at #RPSconf22
pharmaceutical-journal.com/a…
Paul Aliu retweeted
Novartis has been fighting leprosy for more than 40 years, and we remain committed to leprosy elimination. Track our journey from the inception of multidrug therapy (MDT) to >7 million patients treated worldwide.
#BeatNTDs @WHO @ZeroLeprosy @fiocruz @Microsoft @NovartisFDN
Paul Aliu retweeted
Pharmacists should be helping to ensure that 'compassionate use' regulations evolve to address urgent patient needs, argues @PaulAliu2000 from @Novartis
pharmaceutical-journal.com/a…
Delighted to share my recent opinion piece published in the UK Pharmaceutical Journal (PJ) on the role of pharmacists in facilitating patient access to innovative medicines for serious and life-threatening conditions via Compassion…lnkd.in/eFvMwSwy lnkd.in/ea-MFR7q
Paul Aliu retweeted
We partnered with @NovartisFDN to launch an assessment tool to help decision-makers identify where to best invest resources to enable deployment of #AI solutions in health. Learn about the key takeaways from the initial six countries. https://nitter.cf/t.co/ATmey3ViHE
Paul Aliu retweeted
In this cohort study, the existence and public availability of CU regulations and local clinical trial activity were positively associated with higher CU request rates. #patientaccess #CompassionateUse @PaulAliu2000 ja.ma/3PmGjPD
How patients are repurposing compassionate use biocentury.com/article/64443…
1









